Twist Bioscience Establishes $200M At-The-Market Offering Program

summarizeSummary

Twist Bioscience has initiated a new At-The-Market (ATM) offering program, enabling the company to sell up to $200 million of common stock into the market over time for general corporate purposes.

check_boxKey Events

• New Shelf Registration Filed

  The company filed an S-3ASR automatic shelf registration statement, allowing for the future issuance of various securities including common stock, preferred stock, debt securities, warrants, and units.

• Establishes $200M At-The-Market Program

  A specific sales agreement prospectus was included for an At-The-Market (ATM) offering program, authorizing the sale of up to $200,000,000 of common stock through TD Securities (USA) LLC.

• Potential for Dilution

  The ATM program allows for the sale of approximately 2.35 million shares at the recent market price, representing a potential dilution of about 3.78% of current outstanding shares if fully utilized.

• Proceeds for General Corporate Purposes

  Net proceeds from the offering are intended for working capital and other general corporate purposes, including potential in-licensing, acquisitions, or investments.

auto_awesomeAnalysis

Twist Bioscience has filed an S-3ASR shelf registration statement, which includes the establishment of a new At-The-Market (ATM) offering program. This program allows the company to sell up to $200 million of its common stock from time to time through TD Securities (USA) LLC. While this provides the company with significant financial flexibility for general corporate purposes, including potential acquisitions, it also introduces a potential dilutive overhang for existing shareholders as shares are sold into the market. The timing of this capital raise occurs while the stock is trading near its 52-week high, which is advantageous for the company in terms of proceeds per share.